Digital Platform Renewal for Zolgensma Patient Referral and Treatment System

This opportunity involves the renewal and modernization of a comprehensive digital platform designed to streamline the patient referral and treatment process for Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA). The platform consists of two integrated components: ReferAPatient, which facilitates patient referrals to treatment centers, and TreatAPatient, which supports treatment management and patient care coordination. Potential suppliers should be prepared to enhance functionality, ensure regulatory compliance, improve user experience, maintain data security, and integrate with existing healthcare systems. This renewal aims to expand accessibility and optimize outcomes for SMA patients requiring this specialized therapy.